Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valganciclovir
Drug ID BADD_D02326
Description Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Indications and Usage Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
Marketing Status Prescription
ATC Code J05AB14
DrugBank ID DB01610
KEGG ID D02495
MeSH ID D000077562
PubChem ID 135413535
TTD Drug ID D06GWF
NDC Product Code 55111-762; 60429-846; 63739-076; 27241-158; 16714-765; 70010-051; 0004-0038; 50268-787; 71151-003; 31722-832; 69097-277; 0904-6796; 48433-124; 68084-965; 70069-810
Synonyms Valganciclovir | Ganciclovir L-valyl Ester | Ganciclovir L valyl Ester | Valcyt | Valganciclovir Hydrochloride | Valcyte
Chemical Information
Molecular Formula C14H22N6O5
CAS Registry Number 175865-60-8
SMILES CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.007343%
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.0100.014687%Not Available
Respiratory tract infection11.01.08.017; 22.07.07.0010.001916%Not Available
Device related infection08.07.01.005; 11.01.08.018--
Procedural pain08.01.08.009; 12.02.05.007--Not Available
Bone marrow failure01.03.03.0050.009791%
Treatment failure08.06.01.0170.001277%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.005--Not Available
Candida infection11.03.03.021--
Systemic infection11.01.08.050--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
Cytomegalovirus test positive13.08.03.0140.014687%Not Available
The 8th Page    First    Pre   8    Total 8 Pages